The acquisition will enable Amgen to further its research and improve the development of cancer-targeting treatments.
Read more: Biotech Amgen acquires UK-based Dark Blue Therapeutics in $840m deal
•
The acquisition will enable Amgen to further its research and improve the development of cancer-targeting treatments.
Read more: Biotech Amgen acquires UK-based Dark Blue Therapeutics in $840m deal